Plant-based ingredient for reducing food noise and appetite
ASD-NP6 is a patented plant-based ingredient designed to reduce 'food noise' by activating natural gut hormone feedback mechanisms without the side effects of hormone mimetics. It offers a clean label solution for appetite suppression and weight management.
Overview
ASD-NP6 is an innovative plant-based food and beverage ingredient developed to naturally reduce 'food noise' and suppress appetite. Unlike traditional hormone mimetics, ASD-NP6 mimics the natural feedback mechanism of the gut without causing gastrointestinal side effects. The ingredient works by activating the 'ileal break', leading to the release of gut hormones PYY and OXM, which slow down gastric emptying and promote satiety. This clean label solution offers a promising approach to weight management and appetite control, leveraging natural components that seamlessly integrate into the Western diet.
Technical specifications
Key components:
- α-Cyclodextrin (αCD): A soluble resistant fiber and natural carrier of fatty acids, recognized as safe (GRAS 0155) in the US.
- C10 Fatty Acid: Derived from milk or coconut oil, known for its role in appetite suppression.
Mechanism of Action:
- ASD-NP6 forms when two αCD molecules align on a C10 carbon chain, creating a clathrate that travels to the intestine.
- Upon reaching the intestinal wall, C10 is absorbed intra-cellularly, while αCD is absorbed peri-cellularly, facilitating the removal of 'bad' fatty acids and reducing appetite.
Benefits:
- Reduces 'food noise' without direct CNS receptor binding, avoiding common side effects like nausea and vomiting.
- Promotes natural appetite suppression, supporting weight management.
Technology readiness level
ASD-NP6 has achieved a Technology Readiness Level of 8, indicating it has been validated in real-world settings and is ready for commercial deployment. The ingredient has undergone extensive clinical trials and demonstrated effectiveness in reducing appetite and food noise without adverse effects.
About ASDERA
ASDERA is a biotechnology company that develops targeted medical interventions by utilizing a patented computational biostatistics platform. This approach identifies complex genetic risk factors that were often considered inconclusive in other studies, particularly within small-scale epidemiological data or previously failed phase 2/3 clinical trials. By analyzing genetic structures and neighborhood hotspots, the company aims to uncover missing heritability and translate these findings into therapeutic candidates for conditions with significant unmet medical needs. ASDERA operates as a virtual organization that outlicenses its patented assets once development milestones are achieved.
The company focuses on therapeutic areas including aging-related health, oncology, and orphan diseases. Its pipeline includes candidates for developmental language disorders in children at risk of autism, lysosomal storage diseases, and metabolic syndrome, as well as nutritional formulations designed as fasting mimetics to improve aging-related processes. ASDERA serves the broader pharmaceutical and healthcare sector by providing a novel method for drug discovery and asset development. Its research has historically addressed various health challenges, including neurodegeneration, cardiovascular health, and infectious disease responses.
delivered to your inbox.